Ghosh N, et al. - Researchers conducted this single-center retrospective observational cohort study of 127 patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in order to ascertain the utility of calculated AUCs and the optimal AUC_0–24/MIC targets associated with vancomycin treatment success in these patients. No response to vancomycin treatment was noted in 45 patients (35.4 %). Independent predictors of treatment failure were source of bacteraemia and not achieving an AUC_0–24/MIC_BMD (using broth microdilution) target of ≥ 398. Findings suggest that AUC_0–24/MIC targets are not accurately suggested by vancomycin trough concentrations and hence these may result in suboptimal outcomes. Estimating AUC based on validated formulae permits individual patient dose optimization, leading to improved treatment success when a vancomycin exposure or AUC_0–24/MIC_BMD of ≥ 398 is achieved.